CPC A61K 38/465 (2013.01) [A61K 35/76 (2013.01); A61P 31/04 (2018.01); C12N 15/113 (2013.01); C12N 2310/20 (2017.05)] | 31 Claims |
1. A method for treating or preventing an infection by Escherichia coli (E. coli) cells in a human or animal subject, wherein the method comprises administering a plurality of transduction particles to the subject, wherein
(a) each transduction particle comprises a nucleic acid encoding a Cas nuclease and a nucleic acid encoding a crRNA or guide RNA that is operable with the Cas nuclease for targeting the genomes of E. coli cells,
wherein (i) each transduction particle is a phage and the nucleic acid encoding the Cas nuclease is integrated into the genome of the phage, or (ii) each transduction particle is a phage capsid and the nucleic acid encoding the Cas nuclease is a phagemid contained in the phage capsid,
wherein the administered transduction particles contact the cells and introduce therein the nucleic acid, wherein the Cas nuclease is expressed in the cells and cuts genomic DNA of the cells, thereby killing the cells or reducing growth or proliferation of the cells in the subject;
(b) the E. coli cells are cells of E. coli phylogroup B2; and
(c) wherein the plurality of transduction particles comprises a first type of transduction particle and a second type of transduction particle, wherein the first type of transduction particle comprises a first adhesion moiety that is capable of recognizing and binding to LPS displayed on the surface of phylogroup B2 E. coli cells, and the second type of transduction particle comprises a second adhesion moiety that is capable of recognizing and binding to Tsx displayed on the surface of phylogroup B2 E. coli cells.
|